Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Multiple Myeloma Drugs Market 2015-2019

Published: Dec-2014 | Format: PDF | Technavio | Number of pages: 115 | Code: MRS - 2711

 

Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight. The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.

 

TechNavio's analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.

 

Covered in this Report

 

This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma.

 

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

 

Key Regions

 

Americas
APAC
EMEA

 

Key Vendors

 

Celgene
Johnson & Johnson
Novartis
Onyx Pharmaceuticals
Sanofi
Takeda Pharmaceutical

 

Other Prominent Vendors

 

AB Science
Abbvie
Aeterna Zentaris
Amgen
Bristol Myers Squibb
Cephalon
Daiichi Sankyo
Genta
Merck Sharp and Dohme
Oncotherapeutics
PharmaMar
Teva

 

Market Driver

 

Presence of Unmet Needs
For a full, detailed list, view our report

 

Market Challenge

 

High Cost of Treatment
For a full, detailed list, view our report

 

Market Trend

 

Growing Public Awareness
For a full, detailed list, view our report

 

Key Questions Answered in this Report

 

What will the market size be in 2019 and what will the growth rate be
What are the key market trends
What is driving this market
What are the challenges to market growth
Who are the key vendors in this market space
What are the market opportunities and threats faced by the key vendors
What are the strengths and weaknesses of the key vendors

Table of Contents


1. Executive Summary
 

2. List of Abbreviations
 

3. Scope of the Report
3.1 Market Overview
3.2 Product Offerings

 

4. Product Profiles
4.1.1 Pomalyst/ Imnovid
4.1.2 Revlimid
4.1.3 Zometa
4.1.4 Doxil/Caelyx
4.1.5 Thalomid/ Thalidomide Celgene
4.1.6 Kyprolis
4.1.7 Mozobil
4.1.8 Velcade

 

5. Market Research Methodology
5.1 Market Research Process
5.2 Research Methodology

 

6. Introduction
 

7. Disease Overview
7.1 Understanding Multiple Myeloma
7.2 Pathophysiology
7.3 Epidemiology
7.4 Diagnosis
7.5 Staging
7.6 Management
7.7 Economic Burden

 

8. Market Landscape
8.1 Market Overview
8.2 Market Size and Forecast
8.3 Five Forces Analysis

 

9. Market Segmentation by Route of Administration
9.1 Oral
9.2 Parenteral

 

10. Market Segmentation by Dosage Form
10.1 Solid
10.2 Liquid

 

11. Geographical Segmentation
 

12. Buying Criteria
 

13. Market Growth Drivers
 

14. Drivers and their Impact
 

15. Market Challenges
 

16. Impact of Drivers and Challenges
 

17. Market Trends
 

18. Trends and their Impact
 

19. Pipeline Portfolio
 

20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Celgene
20.2.2 Johnson & Johnson
20.2.3 Novartis
20.2.4 Onyx
20.2.5 Sanofi
20.2.6 Takeda Pharmaceutical
20.3 Other and Future Prominent Vendors

 

21. Key Vendor Analysis
21.1 Celgene
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Strategy
21.1.4 Business Segmentation by Revenue
21.1.5 Sales by Geography
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 Johnson & Johnson
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2013
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Geographical Segmentation by Revenue 2013
21.2.6 Business Strategy
21.2.7 Recent Developments
21.2.8 SWOT Analysis
21.3 Novartis
21.3.1 Key Facts
21.3.2 Business Description
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Sales by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis
21.4 Onyx Pharmaceuticals
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Marketed Products
21.4.4 Geographical Segmentation
21.4.5 Business Strategy
21.4.6 Recent Developments
21.4.7 SWOT Analysis
21.5 Sanofi
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Geographical Segmentation by Revenue 2013
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Takeda Pharmaceutical
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013
21.6.4 Business Segmentation by Revenue 2013
21.6.5 Geographical Segmentation by Revenue 2013
21.6.6 Business Strategy
21.6.7 Recent Developments
21.6.8 SWOT Analysis

 

22. Other Reports in this Series
 

List of Exhibits:
 

Exhibit 1: Market Research Methodology
Exhibit 2: Pathophysiology of Multiple Myeloma
Exhibit 3: Indicators of Multiple Myeloma
Exhibit 4: Laboratory Tests to Identify Multiple Myeloma
Exhibit 5: Diagnosis of Multiple Myeloma
Exhibit 6: Staging of Multiple Myeloma
Exhibit 7: Management of Multiple Myeloma
Exhibit 8: Induction Therapy Recommendations for the Transplant Eligible Candidates
Exhibit 9: Maintenance Therapy for the Candidates with Multiple Myeloma
Exhibit 10: Supportive Therapy for the Candidates with Multiple Myeloma
Exhibit 11: Estimated Expenditure for the Four Type of Treatment Regimens for Multiple Myeloma in the US
Exhibit 12: Snapshot of the Economic Burden of Multiple Myeloma
Exhibit 13: Snapshot of Global Multiple Myeloma Drugs Market 2014
Exhibit 14: Global Multiple Myeloma Drugs Market 2014-2019 (US$ million)
Exhibit 15: Global Multiple Myeloma Drugs Market Segmentation By Route Of Administration
Exhibit 16: Global Multiple Myeloma Drugs Market Segmentation by Route of Administration 2014
Exhibit 17: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form
Exhibit 18: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form 2014
Exhibit 19: Global Multiple Myeloma Drugs Market by Geographical Segmentation 2014
Exhibit 20: Buying Criteria of Global Multiple Myeloma Drugs Market 2014
Exhibit 21: Growth Drivers of the Global Multiple Myeloma Drugs Market
Exhibit 22: Drivers and their Impact on the Key Customer Category of Global Multiple Myeloma Drugs Market 2014
Exhibit 23: Drivers and their Impact on the Geographies of Global Multiple Myeloma Drugs Market 2014
Exhibit 24: Challenges of the Global Multiple Myeloma Drugs Market
Exhibit 25: Trends of the Global Multiple Myeloma Drugs Market
Exhibit 26: Phase III Pipeline Molecules for Multiple Myeloma
Exhibit 27: Global Multiple Myeloma Drugs Market Share Analysis 2014
Exhibit 28: Sales Forecast of Pomalyst 2014-2018 (US$ million)
Exhibit 29: YoY Sales Comparison of Revlimid 2007-2013 (US$ million)
Exhibit 30: Sales Forecast of Revlimid 2014-2018 (US$ million)
Exhibit 31: YoY Sales Comparison of Thalomid 2007-2013 (US$ million)
Exhibit 32: Sales Forecast of Thalomid 2014-2018 (US$ million)
Exhibit 33: YoY Sales Comparison of Velcade outside the US 2008-2013 (US$ million)
Exhibit 34: Sales Comparison of Zometa in the US and ROW 2007-2013 (US$ million)
Exhibit 35: Global YoY Sales Comparison of Zometa 2007-2013 (US$ million)
Exhibit 36: YoY Sales Comparison of Zometa in the US 2007-2013 (US$ million)
Exhibit 37: YoY Sales Comparison of Zometa in ROW 2007-2013 (US$ million)
Exhibit 38: Sales Forecast of Kyprolis 2014-2018 (US$ million)
Exhibit 39: Global YoY Sales Comparison of Mozobil 2007-2013 (US$ million)
Exhibit 40: Global YoY Sales Comparison of Velcade in Japan 2009-2013 (US$ million)
Exhibit 41: Sales Forecast of Velcade 2014-2018 (US$ million)
Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 43: Celgene: Sales by Geography 2013
Exhibit 44: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 45: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 46: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 47: Novartis AG: Business Segmentation
Exhibit 48: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 49: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 50: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 51: Onyx Pharmaceuticals: Marketed Products
Exhibit 52: Onyx Pharmaceuticals: Geographical Segmentation
Exhibit 53: Sanofi: Business Segmentation by Revenue 2013
Exhibit 54: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 55: Sanofi: Geographical Segmentation by Revenue 2013
Exhibit 56: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 57: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 58: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3000 View Pricing